Munaza Riaz, Ph.D., a 2023 graduate of the University of Florida College of Pharmacy’s department of pharmaceutical outcomes and policy, has successfully published four papers from her dissertation. These publications significantly contribute to the literature on heart failure with preserved ejection fraction, or HFpEF, and have been recognized at the International Society for Pharmacoeconomics and Outcomes Research, or ISPOR, conferences.
Research on HFpEF addresses a complex subset of heart failure patients with limited treatment options. Riaz’s work focuses on pharmacotherapy trends, the effectiveness and safety of sacubitril/valsartan and sodium-glucose cotransporter-2 inhibitors in patients with HFpEF, thus providing real-world evidence beyond controlled clinical trials.
Her published articles include:
- “Trends in Pharmacotherapy Utilization Among Patients with Heart Failure with Preserved Ejection Fraction”
Read the article - “Comparative Effectiveness of Sodium‐Glucose Cotransporter‐2 Inhibitors Among Patients with Heart Failure with Preserved Ejection Fraction”
Read the article - “Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin Receptor Blockers in Patients with Heart Failure with Preserved Ejection Fraction: A Real-World Study”
Read the article - “Comparative Genitourinary Safety of In-Class Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study”
Read the article
These papers were presented at ISPOR conferences in 2023 and 2024, with her final paper being recognized as a finalist among the Top 5% of abstracts at the ISPOR 2024 conference, highlighting its quality and impact.